


## 4baseCare inaugurates new genomics lab and unveils Global Cancer Diversity Atlas

14 May 2025 | News

**To offer advanced genomic testing solutions including comprehensive gene panels**



4baseCare, a precision oncology company, has inaugurated its new genomics laboratory in Mahadevapura, Bengaluru, as a part of its consistent efforts to advance access to precision oncology in India. The highlight of the launch event was the unveiling of Global Cancer Diversity Atlas (GCDA) aimed at addressing the genomics data gap that exists in cancer care.

The launch event was presided over by N. R. Narayana Murthy, Chairman, Infosys, who also unveiled the Global Cancer Diversity Atlas.

4baseCare's new genomics lab in Bengaluru will offer advanced genomic testing solutions including comprehensive gene panels, whole exome sequencing, and transcriptome analysis. These tools will enable oncologists to delve deeper into the genetic makeup of tumors, offering personalized and more effective cancer treatment options.

The Global Cancer Diversity Atlas (GCDA) is a pioneering initiative by 4baseCare designed to address a critical gap in global cancer research: the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, GCDA is built on real-world data from India and the Global South, including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. GCDA is the world's most inclusive cancer genomics dataset, transforming how we develop diagnostics, conduct research, and deliver cancer care so that every patient, everywhere, is truly seen and understood.

Commenting on the new lab and the unveiling of GCDA, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, "Our new genomics lab and the unveiling of the GCDA are driven by a single goal of creating better access to precision oncology. One of the key challenges in cancer care today is the lack of genomic data from Indian and Asian populations. This data gap has a significant impact on the effectiveness of cancer diagnostics and treatment strategies for under-represented communities."